Showing 7831-7840 of 10617 results for "".
- Study Uses Powerful New ‘Digital Cohort’ Method to Understand Vaping Epidemichttps://reachmd.com/news/study-uses-powerful-new-digital-cohort-method-to-understand-vaping-epidemic/2467120/To leverage these data for scientific insights, the research team analyzed an aggregated sample of data. Among randomly sampled accounts belonging to people who vaped, the researchers found that 27% reported making an attempt to quit during the study period. Of all first quit
- Promising Osteoporosis Drug Target Uncovered in New Studyhttps://reachmd.com/news/promising-osteoporosis-drug-target-uncovered-in-new-study/2467104/Osteoporosis is a skeletal condition that leads to the weakening of bones, making them porous, fragile, and prone to breakage. A whopping 8.9 million fractures are caused by osteoporosis annually, with one fracture occurring every three seconds! The aging population is the most vul
- New Study Suggests Cancer Drug Could Be Used to Target Protein Connection That Spurs Parkinson’s Diseasehttps://reachmd.com/news/new-study-suggests-cancer-drug-could-be-used-to-target-protein-connection-that-spurs-parkinsons-disease/2467080/FOR IMMEDIATE RELEASEIn studies with genetically engineered mice, Johns Hopkins Medicine researchers say they have identified a potentially new biological target involving Aplp1, a cell surface protein that drives the spread of Parkinson’s disease-causing alpha-synuclein.
- New Psychotherapy Shows Promise in Reducing Chronic Pain for Older Veteranshttps://reachmd.com/news/new-psychotherapy-shows-promise-in-reducing-chronic-pain-for-older-veterans/2467082/A new study led by UCLA Health and the U.S. Veterans Affairs Office found chronic pain among older adults could be significantly reduced through a newly developed
- Mothers Lower Risk of Caesarean Births After COVID Vaccinationhttps://reachmd.com/news/mothers-lower-risk-of-caesarean-births-after-covid-vaccination/2467066/Mothers lower risk of caesarean births after COVID vaccinationGlobal meta-analysis of 1.8m women found vaccines led to 61% lower odds of infection during pregnancy and lower odds of hypertension and neonatal ICU admission
- Sleep Disorders in Childhood Increase the Risk of Developing Symptoms of Attention Deficit Disorder and Hyperactivityhttps://reachmd.com/news/sleep-disorders-in-childhood-increase-the-risk-of-developing-symptoms-of-attention-deficit-disorder-and-hyperactivity/2467074/An investigation by CIBER led by Llúcia González-Safont, a researcher in the area of Epidemiology and Public Health (CIBERESP) from the Faculty of Nursing and Podiatry at the University of Valencia and visiting lecturer at the
- Ensuring ‘Pediatric Readiness’ in Emergency Departments Costs Little and Saves Liveshttps://reachmd.com/news/ensuring-pediatric-readiness-in-emergency-departments-costs-little-and-saves-lives/2467075/AUSTIN, Texas — The price tag for making hospital emergency departments ready to provide basic care to children is minimal — ranging from just $4 to $48 per patient — while significantly improving survival rates, according to a
- Study: Advanced AI Enhances Melanoma Detectionhttps://reachmd.com/news/study-advanced-ai-enhances-melanoma-detection/2467071/A new study suggests a novel deep-learning model based on diagnostic data may help harness the power of neural networks and artificial intelligence (AI) to more accurately diagnose melanoma.
- FDA Approves New Tralokinumab-ldrm Autoinjectorhttps://reachmd.com/news/fda-approves-new-tralokinumab-ldrm-autoinjector/2467047/The US Food and Drug Administration (FDA) announced the approval of a new tralokinumab-ldrm 300-mg single-dose autoinjector for adult patients. Adbry® (LEO Pharma Inc.), a high-affinity fully human monoclonal antibody, is currently indicated in the US for the treatment of moderate-to-sever
- FDA Approves Adbry Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)https://reachmd.com/news/fda-approves-adbry-autoinjector-treatment-adults-moderate-severe-atopic-dermatitis-ad/2467043/The FDA has approved LEO Pharma's Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.1 The new autoinjector (300 mg/2 mL) will provide another option for adult patients in addit